In summary, results from our studies further validated IL-1R7 as a potential therapeutic target and set the stage for a full characterization of the potential of anti-IL-1R7 in clinical studies of IL-18-mediated diseases such as MAS, COVID-19, IBD and rheumatic diseases (5, 8). This evidence concerns the gene IL18RAP and COVID-19.